APYX MEDICAL CORP
APYXNASDAQTrading Snapshot
- Day Range
- $2.59 – $2.63
- 52-Week Range
- $1.89 – $5.08
- Volume
- $2.82B
- Avg Volume
- $3.18B
- Shares Outstanding
- 41.9M
- Next Earnings
- Nov 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $53M
- Last Q Revenue
- $14M
- P/E Ratio
- —
- P/S Ratio
- 1.9x
- EPS (TTM)
- $-0.20
- Dividend Yield
- —
- Dilution (1yr)
- +10.3%
Why Investors Own APYX
- ✓High-growth profile — revenue up +9.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
APYX MEDICAL CORP
APYX
StockOtter · stockotter.spaceAbout APYX MEDICAL CORP
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality
CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring
Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring
Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been resha
Apyx Medical Corporation (NASDAQ:APYX) Receives $6.60 Consensus Target Price from Brokerages
Apyx Medical Corporation (NASDAQ: APYX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rate
Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
Apyx Medical Q2 Earnings Call Highlights
Apyx Medical NASDAQ: APYX reported second-quarter revenue growth of 22% as sales in its surgical aesthetics business increased, led by adoption of its AYON Body Contouring System, international generator sales and domest
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring Sy